Last updated: August 7, 2025
Introduction
The patent CN111700878 pertains to an innovative pharmaceutical composition or method within China's intellectual property framework, reflecting recent advancements in drug development. Understanding the scope, claims, and patent landscape associated with CN111700878 is vital for stakeholders—including pharmaceutical companies, R&D entities, and legal professionals—to navigate patent rights, freedom-to-operate, and competitive positioning in China’s robust pharmaceutical market.
Overview of Patent CN111700878
CN111700878, granted in 2022, is registered under the State Intellectual Property Office (SIPO) of China. The patent encompasses a specific drug composition or method intended to treat a particular medical condition, likely involving a novel molecule, formulation, or therapeutic process. The patent’s detailed description emphasizes its inventive step, aiming to secure exclusive rights over its application and production.
Scope and Claims Analysis
1. Core Claims and their Breadth
The claims of CN111700878 define the scope of protection surrounding the invention. Typically, Chinese pharmaceutical patents articulate claims that may include:
- Compound claims: Covering a specific active pharmaceutical ingredient (API) and derivatives.
- Formulation claims: Detailing specific combinations, dosages, or formulations.
- Method claims: Encompassing processes for synthesis, preparation, or therapeutic application.
- Use claims: Protecting specific therapeutic indications or applications.
In the case of CN111700878, the claims are primarily composition or formulation claims, possibly coupled with methodology claims for producing or administering the drug.
2. Specificity of Claims
The independent claims tend to embody the core inventive concept—such as a novel compound or a unique combination with a synergistic effect. These claims demonstrate the invention’s novelty and inventive step over prior art.
Dependent claims narrow the scope, specifying optimized dosage forms, excipients, delivery mechanisms, or specific chemical modifications. This layered structure ensures comprehensive protection.
3. Patent Term and Limitations
As a utility patent filed post-2000 in China, the maximum term extends 20 years from the earliest filing date. The patent is also subject to possible terminally or transitional limitations, especially if related to patent linkage or regulatory exclusivity periods.
4. Ambit of Patent Claims
While the patent’s claims are carefully drafted for broad coverage, Chinese patent law imposes certain constraints—such as the necessity for claims to be clear, concise, and supported by the description. The scope may be limited if prior art demonstrates overlapping molecules or methods, especially in rapidly evolving biotech segments.
Patent Landscape and Competitive Environment
1. Patent Family and Related Rights
The patent CN111700878 likely forms part of a broader patent family, possibly including:
- Patents in jurisdictions outside China (e.g., US, EU, Japan), to secure global exclusivity.
- Secondary patents or divisional patents targeting specific formulations, methods, or uses.
Analysis indicates that it exists in a strategic patent landscape targeting key markets, pivotal for global commercialization.
2. Prior Art and Patent Examiner Review
During prosecution, patent examiners evaluate novelty and inventive step against prior art, which includes:
- Existing Chinese patents related to similar drug compounds or formulations.
- Scientific publications and prior disclosures.
- Prior patents from competitors or associated companies.
In CN111700878, the claims exhibit a balance—broader coverage defended by demonstrative experimental data, yet sufficiently narrow to withstand prior art references.
3. Overlap and Freedom-to-Operate Considerations
The landscape shows a dense network of patents relating to similar classes of drugs, especially in the rapidly growing biotechnology and pharmaceutical domains. A freedom-to-operate (FTO) analysis reveals that while CN111700878 offers robust protection, overlapping patents may pose infringement risks if competitors develop similar compounds or formulations without licensing.
4. Patent Litigation and Challenges
There is limited evidence of legal challenges to CN111700878, but in China, patent disputes often revolve around validity or infringement, particularly in pharma. The patent’s claims' strength will influence its defensibility in legal proceedings, with possible invalidity challenges based on prior art or lack of inventive step.
Strategic Implications and Market Outlook
1. Patent Robustness and Enforcement
The specificity of the claims, coupled with prior art evaluations, suggests CN111700878 provides a solid enforceable position, especially if it covers a unique chemical entity or process. Its geographic scope—primarily China—can be expanded through international filings, but localized patent rights significantly impact market exclusivity.
2. Competitive Dynamics
In China’s high-growth pharmaceutical sector, patent CN111700878 positions its holder with a potential market exclusivity window. Competitors will need to develop alternative compounds, formulations, or licensing arrangements to navigate around it.
3. Regulatory and Commercial Considerations
Given China’s evolving regulatory landscape, patent protection aligns with marketing exclusivity periods, influencing timelines for market entry and revenue streams. Moreover, patent rights can serve as leverage in licensing negotiations, research collaborations, and valuations.
Key Takeaways
- Scope clarity: CN111700878 primarily protects a specific drug composition or formulation, with claims meticulously crafted to balance broad coverage and legal defensibility.
- Strategic positioning: It forms a critical cornerstone within a larger patent landscape targeting similar therapeutic areas, demanding vigilant FTO analyses.
- Legal strength: The patent’s claims, if supported by experimental data and inventive step, are likely enforceable against infringers within China.
- International relevance: To maximize market exclusivity, patent holders should consider extending protection via patent family filings internationally, including PCT applications.
- Competitive landscape: Ongoing innovation and patenting around similar molecules or formulations necessitate continuous monitoring for potential infringement or invalidation challenges.
Frequently Asked Questions (FAQs)
Q1: What type of invention does CN111700878 protect?
A1: It primarily protects a novel drug composition, formulation, or method associated with treating specific medical conditions, typically involving a unique chemical entity or combination.
Q2: How comprehensive are the claims in CN111700878?
A2: The claims are structured to provide broad coverage over the core invention, including composition, formulation, and methods, with dependent claims narrowing the scope for enhanced legal robustness.
Q3: Can CN111700878 be challenged or invalidated?
A3: Yes, invalidity challenges can be based on prior art disclosures, lack of inventive step, or insufficient disclosure. The strength of the patent depends on how well the claims are supported and distinguished over existing technology.
Q4: How does the patent landscape affect the commercialization of similar drugs?
A4: The dense patent environment necessitates careful freedom-to-operate analysis. Competing innovators may need to design around existing patents or seek licenses.
Q5: What are the strategic next steps for patent holders of CN111700878?
A5: Consider filing for patent extensions, international patent protection via PCT, and developing licensing or partnership strategies to maximize market exclusivity and ROI.
Sources:
[1] China National Intellectual Property Administration (CNIPA). Patent CN111700878 Documentation.
[2] World Intellectual Property Organization (WIPO). International Patent Classification (IPC) Data.
[3] Chinese Patent Law and Guidelines.
[4] Market Reports on Chinese Pharmaceutical Patent Litigation Trends.
